| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8461333 | VIIV HLTHCARE | Salts of prodrugs of piperazine and substituted piperidine antiviral agents |
Feb, 2025
(10 months from now) | |
| US7745625 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Nov, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168615 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Feb, 2025
(10 months from now) | |
Rukobia is owned by Viiv Hlthcare.
Rukobia contains Fostemsavir Tromethamine.
Rukobia has a total of 3 drug patents out of which 0 drug patents have expired.
Rukobia was authorised for market use on 02 July, 2020.
Rukobia is available in tablet, extended release;oral dosage forms.
Drug patent challenges can be filed against Rukobia from 02 July, 2024.
The generics of Rukobia are possible to be released after 19 November, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2025 |
Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient
NCE-1 date: 02 July, 2024
Market Authorisation Date: 02 July, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
More Information on Dosage
RUKOBIA family patents
